moomoo ID:0
Log Out
  • English
  • 中文繁体
  • 中文简体

Head to Head Survey: Dynatronics (NASDAQ:DYNT) Versus NovoCure (NASDAQ:NVCR)

Defense World ·  11/30/2022 15:22

NovoCure (NASDAQ:NVCR – Get Rating) and Dynatronics (NASDAQ:DYNT – Get Rating) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings , analyst recommendations, risk, valuation, dividends and institutional ownership.

Earnings and Valuation

This table compares NovoCure and Dynatronics' revenue, earnings per share and valuation.

Get NovoCure alerts:
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NovoCure $535.03 million 14.65 -$58.35 million ($0.77) -96.99
Dynatronics $44.34 million 0.19 -$3.99 million ($0.32) -1.38

Dynatronics has lower revenue, but higher earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Dynatronics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

76.5% of NovoCure shares are owned by institutional investors. Comparatively, 8.5% of Dynatronics shares are owned by institutional investors. 6.2% of NovoCure shares are owned by company insiders. Comparatively, 10.9% of Dynatronics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

NovoCure has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Comparatively, Dynatronics has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500.


This table compares NovoCure and Dynatronics' net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NovoCure -15.05% -18.85% -7.06%
Dynatronics -11.30% -33.81% -13.68%

Analyst Recommendations

This is a breakdown of recent recommendations for NovoCure and Dynatronics, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NovoCure 1 1 5 0 2.57
Dynatronics 0 0 2 0 3.00

NovoCure currently has a consensus target price of $102.00, indicating a potential upside of 36.58%. Dynatronics has a consensus target price of $4.00, indicating a potential upside of 809.09%. Given Dynatronics' stronger consensus rating and higher probable upside, analysts clearly believe Dynatronics is more favorable than NovoCure.

About NovoCure

(Get Rating)

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

About Dynatronics

(Get Rating)

Dynatronics Corporation, a medical device company, designs, manufactures, and sells physical therapy, rehabilitation, orthopedics, pain management, and athletic training products in the United States. The company offers orthopedic soft bracing products include cervical collars, shoulder immobilizers, arm slings, wrist and elbow supports, abdominal and lumbosacral supports, maternity supports, knee immobilizers and supports, ankle walkers and supports, plantar fasciitis splints, and cold therapy products; and therapeutic modality devices comprising electrotherapy, ultrasound, phototherapy, traction, hot and cold therapy, and electrodes. It also offers power and manually operated treatment tables, mat platforms, work tables, parallel bars, training stairs, weight racks, and other related equipment. In addition, the company provides clinical supplies, including exercise bands and tubing, lotions and gels, orthopedic bracings, paper products, and other related supplies. It markets its products under the Dynatron, Dynatron Solaris, Dynaheat, BodyIce, Powermatic, Bird & Cronin, Physician's Choice, Hausmann, PROTEAM, and Mammoth brands. The company sells its products to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, and hospitals. It also exports its products. Dynatronics Corporation was founded in 1979 and is headquartered in Eagan, Minnesota.

Receive News & Ratings for NovoCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure and related companies with's FREE daily email newsletter.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites and Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.